Mechanisms and technologies in cancer epigenetics
Frontiers in Oncology,
Год журнала:
2025,
Номер
14
Опубликована: Янв. 7, 2025
Cancer's
epigenetic
landscape,
a
labyrinthine
tapestry
of
molecular
modifications,
has
long
captivated
researchers
with
its
profound
influence
on
gene
expression
and
cellular
fate.
This
review
discusses
the
intricate
mechanisms
underlying
cancer
epigenetics,
unraveling
complex
interplay
between
DNA
methylation,
histone
chromatin
remodeling,
non-coding
RNAs.
We
navigate
through
tumultuous
seas
dysregulation,
exploring
how
these
processes
conspire
to
silence
tumor
suppressors
unleash
oncogenic
potential.
The
narrative
pivots
cutting-edge
technologies,
revolutionizing
our
ability
decode
epigenome.
From
granular
insights
single-cell
epigenomics
holistic
view
offered
by
multi-omics
approaches,
we
examine
tools
are
reshaping
understanding
heterogeneity
evolution.
also
highlights
emerging
techniques,
such
as
spatial
long-read
sequencing,
which
promise
unveil
hidden
dimensions
regulation.
Finally,
probed
transformative
potential
CRISPR-based
epigenome
editing
computational
analysis
transmute
raw
data
into
biological
insights.
study
seeks
synthesize
comprehensive
yet
nuanced
contemporary
landscape
future
directions
research.
Язык: Английский
FCRL1 and BAFF mRNA Expression as Novel Diagnostic and Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma: Expression Signatures Predict R-CHOP Therapy Response and Survival
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(3), С. 1269 - 1269
Опубликована: Янв. 31, 2025
This
study
investigated
the
diagnostic,
prognostic,
and
therapeutic
significance
of
Fc
receptor-like
1
(FCRL1)
B-cell
activating
factor
(BAFF)
mRNA
expression
in
Egyptian
patients
with
diffuse
large
lymphoma
(DLBCL)
undergoing
standard
R-CHOP
regimen
(rituximab,
cyclophosphamide,
doxorubicin,
vincristine,
prednisone)
using
quantitative
real-time
PCR
(RT-qPCR).
The
results
demonstrated
that
FCRL1
BAFF
were
significantly
elevated
DLBCL
compared
to
healthy
controls.
A
strong
positive
correlation
existed
between
levels.
Diagnostic
performance
assessed
through
combined
ROC
curve
analysis
revealed
BAFF,
FCRL1,
lactate
dehydrogenase
(LDH)
achieved
perfect
diagnostic
accuracy
(AUC
=
1.0),
demonstrating
100%
sensitivity,
specificity,
predictive
values.
Further
prognostic
COX
regression
identified
as
most
significant
predictor
poor
clinical
outcomes.
Kaplan–Meier
survival
reinforced
this
finding,
high
showing
associations
reduced
overall
(OS,
p
0.031)
progression-free
(PFS,
0.038).
underscores
potential
utility
markers
for
DLBCL,
emerging
a
promising
marker
target
enabling
more
tailored
treatment
approaches
common
type
non-Hodgkin
lymphoma,
receiving
therapy.
Язык: Английский
Bioequivalence of generic and branded ibrutinib capsules in healthy Chinese volunteers under fasting and fed conditions: a randomized, four-period, fully replicated, crossover study
Expert Opinion on Drug Metabolism & Toxicology,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 23, 2025
The
aim
of
this
study
was
to
evaluate
the
bioequivalence
test
and
reference
products
ibrutinib
capsule
(140
mg).
This
a
fully
replicated
crossover
that
included
100
healthy
Chinese
volunteers
(50
in
fasting
BE
50
fed
study).
Subjects
were
assigned
receive
single
dose
or
product
each
treatment
period.
main
PK
parameters
(Cmax,
AUC0-t,
AUC0-∞)
evaluated
using
either
average
(ABE)
approach
reference-scaled
(RSABE)
approach,
depending
on
within-subject
standard
deviation
(SWR)
estimated
study.
RSABE
applied
Cmax
as
corresponding
SWR
value
exceeded
cutoff
0.294,
while
ABE
AUC0-t
AUC0-∞
values
less
than
0.294.
All
three
met
acceptance
criteria
both
studies.
are
bioequivalent
under
conditions.
also
confirmed
high
intra-subject
variability
for
ibrutinib.
http://www.chinadrugtrials.org.cn/index.html
identifier
is
CTR20202168.
Язык: Английский
Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(21), С. 11384 - 11384
Опубликована: Окт. 23, 2024
Diffuse
large
B-cell
lymphoma
(DLBCL)
is
a
malignancy
of
immense
biological
and
clinical
heterogeneity.
Based
on
the
transcriptomic
or
genomic
approach,
several
different
classification
schemes
have
evolved
over
years
to
subdivide
DLBCL
into
clinically
(prognostically)
relevant
subsets,
but
each
leaves
unclassified
samples.
Herein,
we
outline
tumor
biology
behind
actual
potential
drug
targets
address
challenges
drawbacks
coupled
with
their
(potential)
use.
Therapeutic
modalities
are
discussed,
including
small-molecule
inhibitors,
naked
antibodies,
antibody-drug
conjugates,
chimeric
antigen
receptors,
bispecific
antibodies
T-cell
engagers,
immune
checkpoint
inhibitors.
Candidate
drugs
explored
in
ongoing
trials
diverse
toxicity
issues
refractoriness
drugs.
According
literature
DLBCL,
promise
for
new
therapeutic
lies
epigenetic
alterations,
receptor
NF-κB
pathways.
present
putative
hiding
lipid
pathways,
ferroptosis,
gut
microbiome
that
could
be
used
addition
immuno-chemotherapy
improve
general
health
status
patients,
thus
increasing
chance
being
cured.
It
may
time
devote
more
effort
exploring
metabolism
discover
novel
druggable
targets.
We
also
performed
bibliometric
knowledge-map
analysis
published
from
2014-2023.
Язык: Английский